University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
J

The Big Question in CLL Frontline Therapy: How to Choose Between Ibrutinib, Acalabrutinib & Venetoclax?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
282 views
May 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
CLL Therapy in 2019
13:16

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmun…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

154 views
07:09

The Big Question in CLL Frontline Therapy: How to Choose Between Ibr…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

282 views
24:51

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Vene…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Davids

56 views